On December 16, 2013 Alcobra announced its lead drug compound MG01C1 had TOVA and CAARS Scores equal to if not better than all existing players (this is how the industry measures efficacy in ADHD). Based upon their involuntary read out, I believe the stock is highly undervalued. Since December 20th, the stock has risen 20%; however, as I dig deeper within the December 16th report, it appears to be a major inflection point within their business. Dr. Yaron Daniely (the CEO of Alcobra) has publicly stated that their corporate strategy pending positive phase III results is to sell the company.
ADHD is one of the most common behavioral disorders in the world. Alcobra has stated that the market...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|